title: Clinical significance of peritumoral lymphatic vessel density and lymphatic vessel invasion detected by D2-40 immunostaining in FIGO Ib1-IIa squamous cell cervical cancer.
abstract: The clinical significance of lymphangiogenesis in cervical cancer remains controversial. Our aim was to investigate the correlation between lymphangiogenesis, lymphatic vessel invasion (LVI) and tumor metastasis, invasion and prognosis in squamous cell cervical cancer. Paraffin sections of 90 patients with FIGO (Fédération Internationale de Gynécologie et d'Obstétrique) Ib1-IIa squamous cell cervical cancer were stained for immunohistochemistry with a D2-40 monoclonal antibody against the carcinoembryonic antigen M2A. The lymphatic vessel density (LVD) and LVI were measured, and their relationship with the clinicopathological data was analyzed. D2-40-positive lymphatic vessels were found in 75 of the 90 patients (83.3 %). All D2-40-positive vessels were located in peritumoral areas. The mean±SD of the peritumoral LVD was 10.08±4.16. The positive rate of LVI was 32.0 % (24/75). The recurrence rate of patients with LVD >10 (62.1 %, 18/29) was significantly higher than that of patients with LVD ≤10 (34.8 %, 16/46, P = 0.021). The 5-year recurrence-free survival rate of patients with LVD >10 (41.0 %) was significantly lower than that of patients with LVD ≤10 (67.0 %, P = 0.045). Univariate analysis showed that the peritumoral LVD (≤10 vs >10) was correlated with LVI (absent vs present, P = 0.016). The peritumoral LVD and LVI showed no correlation with age, FIGO stage, tumor size, tumor grade, depth of invasion, or pelvic lymph node metastasis (all: P > 0.05). Peritumoral lymphangiogenesis was correlated with the recurrence and recurrence-free survival in patients with squamous cell cervical cancer. Examination of peritumoral LVD in these patients might therefore help to estimate the risk of recurrence.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, People's Republic of China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Xiong
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Cao
authors.forename: Hui-Lan
authors.initials: HL
authors.lastname: Rao
authors.forename: Mu-Yan
authors.initials: MY
authors.lastname: Cai
authors.forename: Li-Zhi
authors.initials: LZ
authors.lastname: Liang
authors.forename: Ji-Hong
authors.initials: JH
authors.lastname: Liu
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000276:immunology*; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D042601:Lymphatic Vessels / Q000276:immunology* / Q000473:pathology*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D012008:Recurrence; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C500987:monoclonal antibody D2-40